|
141 |
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
Enthalten in The journal of prevention of Alzheimer's disease Bd. 10, 13.6.2023, Nr. 3, date:9.2023: 418-425
|
|
|
|
142 |
Cerebral small vessel disease genomics and its implications across the lifespan
Enthalten in Nature Communications Bd. 11, 8.12.2020, Nr. 1, date:12.2020: 1-18
|
|
|
|
143 |
ChemInform Abstract: Enantioselective Intramolecular C—H Amination Catalyzed by Engineered Cytochrome P450 Enzymes in vitro and in vivo.
Enthalten in ChemInform Bd. 45, 2014, Nr. 3: no-no. 1 S.
|
|
|
|
144 |
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Enthalten in Nature reviews / Gastroenterology & hepatology Bd. 17, 30.6.2020, Nr. 9, date:9.2020: 557-588
|
|
|
|
145 |
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
Enthalten in Nature medicine Bd. 29, 28.8.2023, Nr. 9, date:9.2023: 2334-2346
|
|
|
|
146 |
Comparison of interactive voice response (IVR) with paper administration of instruments to assess functional status, sexual function, and quality of life in elderly men
Enthalten in Quality of life research Bd. 25, 10.9.2015, Nr. 4, date:4.2016: 811-821
|
|
|
|
147 |
Compound heterozygosity and nonsense mutations in the α1-subunit of the inhibitory glycine receptor in hyperekplexia
Enthalten in Human genetics Bd. 109, 2.8.2001, Nr. 3, date:9.2001: 267-270
|
|
|
|
148 |
Constitution of the System Gallium-Indium
Enthalten in JOM Bd. 4, 29.11.2017, Nr. 1, date:1.1952: 39-42
|
|
|
|
149 |
Correction: Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)
Enthalten in Journal of translational medicine Bd. 22, 30.4.2024, Nr. 1, date:12.2024: 1-2
|
|
|
|
150 |
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Enthalten in Nature Bd. 635, 9.10.2024, Nr. 8038, date:11.2024: 462-471
|
|
Administration
